1. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). The CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39.
2. Bhatt D.L., Marso S.P., Hirsch A.T. et al. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes mellitus. Am J Cardiol 2002;90(6):625- 8.
3. Yusuf S., Zhao F., Mehta S.R. et al.; Clopidogrel in Unstable angina to prevent Re�current Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EnglJ Med 2001;345(7):494-502.
4. Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33.
5. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352(12):1179–89.
6. Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45,852 patientswith acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21.
7. Antman E.M.,HandM.,Armstrong P.W. et al.2007Focused Update oftheACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117(2): 296–329.
8. Steinhubl S.R., Berger P.B., Mann J.T. 3rd et al. Clopidogrel for the Reduction of Events During Observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20.
9. Lagerqvist B.,James S.K., Stenestrand U. et al. Longterm outcomes with drug-eluting stents versus baremetal stents in Sweden. N EnglJ Med 2007;356(10):1009– 19.
10. Kastrati A., Mehilli J., Pache J. et al. Analysis of 14 trial comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007;356(10):1030-9.
11. Fraker T.D.Jr., Fihn S.D., Gibbons R.J. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines forthe management of patients with chronic stableangina. Circulation 2007;116(23):2762–72.
12. Grines C.L., BonowR.O., CaseyD.E.Jr. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the Ameri�can College of Physicians. Circulation 2007;115(6):813–8.
13. Eisenstein E.L., Anstrom K.J., Kong D.F. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297(2):159– 68.
14. Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667– 78.
15. Airoldi F., Colombo A., Morici N. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116(7):745–54.
16. Bhatt D.L., Fox K.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone forthe prevention of atherosclerotic events. N EnglJ Med 2006;354(16):1706– 17.
17. Bhatt D.L., Flather M.D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral areterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49(19):1982–8.
18. Pache J., Kastrati A., Mehith J. et al. Clopidogrel therapy in patients undergoing coronary stenting: value of high-loading-dose regimen. Catheter Cardiovasc Interv 2002;55(4):436–41.
19. Попонина Т.М., Попонина Ю.С., Капилевич Н.А., Ефимова Е.В. Современные подходык профилактике тромботических осложнений у больных с ост- рым коронарным синдромом без подъема сегмента ST. Болезни сердца и сосудов 2009;(4):4-9.
20. Гринштейн Ю.И., Савченко Е.А., Филоненко И.В. и др. Зилт у пациентов с атеросклерозом коронарных артерий после аортокоронарного шунтирования. Предварительные результаты открытого, рандомизированного, сравнительного исследования ЗЕВС. Кардиоваскулярная терапия и профилактика 2008;7(6):43–9.
21. Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваскулярная терапия и профилактика 2009;8(1):51-5.
22. Terpening С.An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. JAm Board Fam Med 2009;22(1):51–6.
